
Tariff-related Litigation Update – 8/22
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.
Access our full library of guidance, white papers, and other resources developed by and for the medical technology industry.

Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.

Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.

A powerful op-ed from AdvaMed’s CEO explaining why tariffs could undermine U.S. medtech innovation, jobs, and patient care—and what must be done.

Focusing on pelvic health, maternity care, and mental health, this White Paper uncovers structural barriers and highlights opportunities to advance equity in women’s health.
Brought to you by AdvaMed®, Medtech POV with Scott Whitaker is a podcast that covers the intersection of medtech and policy from every perspective.

Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through July 25, 2025.

AdvaMed is working with its members to improve how technologies are developed, tested, and used across diverse populations and to advocate for reforms that support equitable access for all patients.

AdvaMed’s latest principles outline how the medtech industry can help close gaps in patient care by expanding access to innovative technologies.

Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through July 18, 2025.